Immunohistochemical and molecular studies on malignant transformation in mature cystic teratoma of the ovary

Journal of Obstetrics and Gynaecology Research

Volumn 24, Issue 2, 1998, Pages 83-90

  Yoshioka, Tomomi ^a,b   Tanaka, Toshinobu ^a  

^a AKITA UNIVERSITY   (Japan)

^b Nakadori Hospital   (Japan)

Author keywords

Mature cystic teratoma; p53; Squamous cell carcinoma; Tumor marker

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; PROTEIN P53; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; MOLECULAR BIOLOGY; OVARY CYST; OVARY TERATOMA; PATHOGENESIS; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 0031924934     PISSN: 13418076     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1447-0756.1998.tb00057.x     Document Type: Article

References (38)

1. Talerman A. Germ cell tumors of the ovary. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract. New York: Springer-Verlag, 1994; 20: 879-884
2. Charpin C, Bahn AK, Zurawski Jr VR, Scully RE. Carcinoembryonic antigen (CEA) and carbohydrate determinant 19-9 (CA 19-9) localization in 121 primary and metastatic ovarian tumors: An immunohistochemical study with the use of monoclonal antibodies. Int J Gynecol Pathol 1982; 1: 231-245
3. Kabawat SE, Bast Jr RC, Bahn AK, Welch WR, Knapp RC, Colvin RB. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC 125. Int J Gynecol Pathol 1983; 2: 275-285
4. Nouwen EJ, Hendrix PG, Dauwe S, Eerdekens MW, De Broe ME. Tumor markers in the human ovary and its neoplasms. A comparative immunohistochemical study. Am J Pathol 1987; 126: 230-242
5. Neunteufel W, Breitenecker G. Tissue expression of CA 125 in benign and malignant lesions of ovary and fallopian tube: A comparison with CA 19-9 and CEA. Gynecol Oncol 1989; 32: 297-302
6. Zhou DJ, Gonzalez-Cadavid N, Ahuja H, Battifora H, Moore GE, Cline MJ. A unique pattern of proto-oncogene abnormalities in ovarian adenocarcinomas. Cancer 1988; 62: 1573-1576
7. Sasano H, Garrett CT, Wilkinson DS, Silververg S, Comerford J, Hyde J. Protooncogene amplification and tumor ploidy in human ovarian neoplasms. Hum Pathol 1990; 21: 382-391
8. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast Jr RC, Berchuck A. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991; 51: 2979-2984
9. Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RCF, Kelly KF, Parkin DE, Haites NE. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993; 53: 2128-2132
10. Kim JW, Cho YH, Kwon DJ, Kim TE, Park TC, Lee JM, Namkoong SE. Aberrations of the p53 tumor suppressor gene in human epithelial ovarian carcinoma. Gynecol Oncol 1995; 57: 199-204
11. Arends MJ, Wyllie AH, Bird CC. Papillomaviruses and human cancer. Hum Pathol 1990; 21: 686-698
12. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577-580
13. Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 1977; 40: 1621-1628
14. Koprowsky H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 1979; 5: 957-972
15. Bast Jr RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331-1337
16. van den Berg FM, Baas IO, Polak MM, Offerhaus GJA. Detection of p53 overexpression in routinely paraffin-embedded tissue of human carcinomas using a novel target unmasking fluid. Am J Pathol 1993; 142: 381-385
17. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immumol Methods 1992; 151: 237-244
18. Volkenandt M, Dicker AP, Fanin R, Banerjee D, Albino A, Bertino JR. Polymerase chain reaction analysis of DNA from paraffin-embedded tissue. In: White BA, ed. Methods in Molecular Biology, vol 15: PCR Protocols: Current Methods and Applications. Totowa: Humana press, 1991; 8: 81-88
19. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989; 5: 874-879
20. Murakami Y, Hayashi K, Sekiya T. Detection of aberrations of the p53 alleles and the gene transcript in human tumor cell lines by single-strand conformation polymorphism analysis. Cancer Res 1991; 51: 3356-3361
21. Makino R, Sekiya T, Hayashi K. Evaluation of quantitative detection of mRNA by the reverse transcription-polymerase chain reaction. Technique 1990; 2: 295-301
22. Naito M, Satake M, Sakai E, Hirano Y, Tshuchida N, Kanzaki H, Ito Y, Mori T. Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis. Jpn J Cancer Res 1992; 83: 1030-1036
23. Suzuki Y, Sekiya T, Hayashi K. Allele-specific polymerase chain reaction: A method for amplification and sequence determination of a single component among a mixture of sequence variants. Analyt Biochem 1991; 192: 82-84
24. Yoshikawa H, Kawana T, Kitagawa K, Mizuno M, Yoshikura H, Iwamoto I. Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers. Jpn J Cancer Res 1991; 82: 524-531
25. Yee C, Krishnan-Hewlett I, Baker CC, Schlegel R, Howley PM. Presence and expression of human papillomavirus sequence in human cervical carcinoma cell lines. Am J Pathol 1995; 119: 361-366
26. Kimura T, Inoue M, Miyake A, Tanizawa O, Oka Y, Amemiya K, Mineta H, Neki R, Nishino H, Morishige K, Yanagida T. The use of serum TA-4 in monitoring patients with malignant transformation of ovarian mature cystic teratoma. Cancer 1989; 64: 480-483
27. Miyazaki K, Tokunaga T, Katabuchi H, Ohba T, Tashiro H, Okamura H. Clinical usefulness of serum squamous cell carcinoma antigen for early detection of squamous cell carcinoma arising in mature cystic teratoma of the ovary. Obstet Gynecol 1991; 78: 562-566
28. Kato H, Miyauchi F, Morioka H, Fujino T, Torigoe T. Tumor antigen of human cervical squamous cell carcinoma. Cancer 1979; 43: 585-590
29. Kato H, Morioka H, Aramaki S, Tamai K, Torigoe T. Prognostic significance of the tumor antigen TA-4 in squamous cell carcinoma of the uterine cervix. Am J Obstet Gynecol 1983; 145: 350-354
30. Halila H, Stenman UH, Seppälä M. Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy. Cancer 1986; 57: 1327-1329
31. Dawood MY, Khan-Dawood FS, Ramos J. Plasma and peritoneal fluid levels of CA 125 in women with endometriosis. Am J Obstet Gynecol 1988; 159: 1526-1531
32. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53
33. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70: 523-526
34. Inoue M, Fujita M, Enomoto T, Morimoto H, Monden T, Shimano T, Tanizawa O. Immunohistochemical analysis of p53 in gynecologic tumors. Am J Clin Pathol 1994; 102: 665-670
35. Kihana H, Tsuda H, Teshima S, Okada S, Matsuura S, Hirohashi S. High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy. Jpn J Cancer Res 1992; 83: 978-984
36. Dürst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 1983; 80: 3812-3815
37. McLellan R, Buscema J, Guerrero E, Shah KV, Woodruff JD, Currie JL. Investigation of ovarian neoplasia of low malignant potential for human papillomavirus. Gynocol Oncol 1990; 38: 383-385
38. Beckmann AM, Sherman KJ, Saran L, Weiss NS. Genital-type human papillomavirus infection is not associated with surface epithelial ovarian carcinoma. Gynecol Oncol 1991; 43: 247-251